Humanigen, Inc. (NASDAQ:HGEN) Expected to Earn Q2 2022 Earnings of ($0.25) Per Share

Humanigen, Inc. (NASDAQ:HGEN – Get Rating) – Research analysts at Oppenheimer upped their Q2 2022 earnings per share estimates for shares of Humanigen in a research note issued on Tuesday, April 19th. Oppenheimer analyst K. Degeeter now forecasts that the company will earn ($0.25) per share for the quarter, up from their previous estimate of ($0.27). Oppenheimer also issued estimates for Humanigen’s FY2022 earnings at ($0.35) EPS.

Separately, Zacks Investment Research raised shares of Humanigen from a “sell” rating to a “hold” rating in a research note on Thursday, February 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Humanigen currently has an average rating of “Hold” and an average target price of $21.00.

Shares of NASDAQ:HGEN opened at $2.06 on Thursday. Humanigen has a 52 week low of $1.67 and a 52 week high of $23.53. The stock has a market capitalization of $134.58 million, a P/E ratio of -0.50 and a beta of -1.46. The firm has a fifty day simple moving average of $2.71 and a two-hundred day simple moving average of $4.05.

Humanigen (NASDAQ:HGEN – Get Rating) last issued its quarterly earnings data on Monday, February 28th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Humanigen had a negative net margin of 6,582.73% and a negative return on equity of 4,882.88%. The business had revenue of $1.04 million during the quarter, compared to analysts’ expectations of $1.01 million.

A number of large investors have recently added to or reduced their stakes in HGEN. Pinnacle Associates Ltd. purchased a new stake in shares of Humanigen in the 4th quarter valued at $39,000. ProShare Advisors LLC purchased a new stake in Humanigen during the fourth quarter worth $40,000. Arizona State Retirement System purchased a new stake in Humanigen during the fourth quarter worth $48,000. Commonwealth Equity Services LLC acquired a new position in Humanigen during the fourth quarter worth $52,000. Finally, Raymond James & Associates acquired a new position in Humanigen during the third quarter worth $60,000. 39.37% of the stock is currently owned by institutional investors.

In other Humanigen news, insider Dale Chappell purchased 1,000,000 shares of Humanigen stock in a transaction dated Friday, March 11th. The stock was acquired at an average price of $3.00 per share, for a total transaction of $3,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Edward P. Jordan purchased 12,500 shares of Humanigen stock in a transaction dated Wednesday, March 2nd. The stock was acquired at an average price of $2.32 per share, with a total value of $29,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 1,059,500 shares of company stock valued at $3,140,310. 27.30% of the stock is owned by corporate insiders.

Humanigen Company Profile (Get Rating)

Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia.

Further Reading